Candel Therapeutics Inc (NASDAQ:CADL) is advancing plans to bring its lead cancer immunotherapy toward potential ...

Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, metastatic, non-squamous, non-small cell lung cancer ...

For more information about Candel, visit: www.candeltx.com.

RTW committed $100M in U.S. launch funding, subject to U.S. Food and Drug Administration (FDA) approval of aglatimagene besadenovec (aglatimagene or CAN-2409) for intermediate- to high-risk localized ...

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635 (c) (4) and were granted ...

Shares of Candel Therapeutics Inc. (CADL) surged over 9% on Friday morning, reaching their highest level in nearly a month ...

Shares of Candel Therapeutics Inc. surged nearly 10% on Wednesday and extended gains in after-hours trading following a ...

Full abstracts will be released by ASCO on Thursday, May 22, 2025, at 5:00 PM ET. Details from the presentations will be available following the event on the Candel website at Candel Media. * Dr.

Century Therapeutics, Candel Therapeutics and MacroGenics have all used their third-quarter earnings releases to disclose how they’re fine-tuning their clinical pipelines to conserve cash. Century has ...

Candel Therapeutics, Inc. (NASDAQ: CADL) shares are down during Friday’s premarket session as the company announced the pricing of a public offering. The stock’s decline follows news that Candel ...

Candel Therapeutics is taking difficult measures to keep its clinical flame burning, laying off 50% of its team as part of a wide scale restructuring meant to save cash for a couple of core programs.